Literature DB >> 9269765

Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain.

S Köchl1, F Fresser, E Lobentanz, G Baier, G Utermann.   

Abstract

Lipoprotein(a) [Lp(a)], which has been shown to interact with fibrin(ogen) and other components of the blood clotting cascade, is a major independent risk factor for atherothrombotic disease in humans. The physiological function(s) of Lp(a), as well as the precise mechanism(s) by which high plasma levels of Lp(a) increase risk are unknown. Identification of further potential apo(a)-protein ligands may be crucial to illuminate apo(a)'s function(s) and pathophysiological properties. We used the repetitive apo(a) kringle IV type 2, which is variable in number in apo(a), to screen a human liver cDNA library by the yeast two-hybrid interaction trap system. Among 11 positive clones that emerged from the screen, eight clones were identified as beta-2 glycoprotein I and one as fibronectin. Coimmunoprecipitation experiments confirmed that beta-2 glycoprotein I and apo(a)/Lp(a) interact in human plasma and in cell culture supernatants of COS-1 cells, which ectopically expressed apo(a). The apo(a)-beta2-glycoprotein I interaction indicates new potential roles for Lp(a) in fibrinolysis and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269765

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

2.  High resolution structure of human apolipoprotein (a) kringle IV type 2: beyond the lysine binding site.

Authors:  Alice Santonastaso; Maristella Maggi; Hugo De Jonge; Claudia Scotti
Journal:  J Lipid Res       Date:  2020-09-09       Impact factor: 5.922

Review 3.  Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene.

Authors:  Stefan Coassin; Florian Kronenberg
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

4.  Studies on specific interaction of beta-2-glycoprotein I with HBsAg.

Authors:  Pu-Jun Gao; Yun-Feng Piao; Xiao-Dong Liu; Li-Ke Qu; Yang Shi; Xiao-Cong Wang; Han-Yi Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

5.  beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.

Authors:  Chunya Bu; Lei Gao; Weidong Xie; Jainwei Zhang; Yuhong He; Guoping Cai; Keith R McCrae
Journal:  Arthritis Rheum       Date:  2009-02

6.  Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome.

Authors:  Fatima El-Assaad; Steven A Krilis; Bill Giannakopoulos
Journal:  Thromb J       Date:  2016-10-04

7.  Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels-Brief Report.

Authors:  George Thanassoulis; James C Engert; Mary Hoekstra; Hao Yu Chen; Jian Rong; Line Dufresne; Jie Yao; Xiuqing Guo; Michael Y Tsai; Sotirios Tsimikas; Wendy S Post; Ramachandran S Vasan; Jerome I Rotter; Martin G Larson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-29       Impact factor: 8.311

8.  Lipoprotein(a).

Authors:  Florian Kronenberg
Journal:  Handb Exp Pharmacol       Date:  2022

Review 9.  Human plasma protein N-glycosylation.

Authors:  Florent Clerc; Karli R Reiding; Bas C Jansen; Guinevere S M Kammeijer; Albert Bondt; Manfred Wuhrer
Journal:  Glycoconj J       Date:  2015-11-10       Impact factor: 2.916

Review 10.  Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role.

Authors:  Alexandros D Tselepis
Journal:  J Biomed Res       Date:  2018-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.